Windtree Therapeutics Inc
WINTDelisted- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946486
Windtree Therapeutics Inc was delisted in 2026; its insiders filed their last Form 4 on Oct 9, 2024; no institution reported holding it in 13F filings for Q2 2026; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2026
- 13F value
- $0
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- –
- No comparable prior period
- Net income, FY2024
- -$1.79M
- No comparable prior period
- Free cash flow, FY2024
- -$15.4M
- No comparable prior period
- Revenue, Q3 FY2025
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 7.75K
- Shares sold short
- Change
- 0
- 0.0% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding WINT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding WINT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Windtree Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2024 (view filing) | Oct 8 | 1 day | Fraser CraigPresident and CEO | PPurchase | +5.43K | $0.91 | +$4.94K | +169.3%8.64K after | |
| Sep 28, 2023 (view filing) | Sep 27 | 1 day | Fraser CraigPresident and CEO | PPurchase | +2.50K | $1.02 | +$2.55K | +4.5%57.9K after | |
| Sep 27, 2023 (view filing) | Sep 26 | 1 day | Fraser CraigPresident and CEO | PPurchase | +2.50K | $0.90 | +$2.25K | +4.7%55.4K after | |
| Apr 27, 2023 (view filing) | Apr 26 | 1 day | Fraser CraigPresident and CEO | PPurchase | +1.50K | $1.77 | +$2.65K | +27.2%7.01K after | |
| Apr 26, 2023 (view filing) | Apr 25 | 1 day | Fraser CraigPresident and CEO | PPurchase | +1.31K | $1.89 | +$2.49K | +31.3%5.51K after | |
| Jul 27, 2022 (view filing)4:20 PM ET | Jul 27 | Same day | Fraser CraigPresident and CEO | PPurchase | +2.50K | $0.3799 | +$949.75 | +1.1%226.6K after | |
| Jul 26, 2022 (view filing)4:38 PM ET | Jul 26 | Same day | Hamill John P.SVP & CFO | PPurchase | +3.00K | $0.3666 | +$1.10K | +4.3%72.8K after | |
| Jul 26, 2022 (view filing)4:37 PM ET | Jul 26 | Same day | Fraser CraigPresident and CEO | PPurchase | +2.50K | $0.374 | +$935 | +1.1%224.1K after | |
| Jul 5, 2022 (view filing)4:40 PM ET | Jun 30 | 5 days | Fraser CraigPresident and CEO | PPurchase | +4.50K | $0.4279 | +$1.93K | +2.1%221.6K after | |
| Jun 30, 2022 (view filing)6:59 AM ET | Jun 29 | 1 day | Fraser CraigPresident and CEO | PPurchase | +7.00K | $0.4154 | +$2.91K | +3.3%217.1K after |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Windtree Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding WINT in 13F filings for Q2 2026.